Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Phase 3 Completed
161 enrolled
ConsortiumIO
Phase 1/2 Completed
56 enrolled 11 charts
ARC-12
Phase 1 Completed
94 enrolled
EARN
Phase NA Completed
33 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Genomic Testing and Resulting Medical Decisions
Completed
1,500 enrolled
PREFER
Completed
1,429 enrolled
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Phase NA Completed
128 enrolled 24 charts
DUET-3
Phase 1 Completed
198 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Phase 1/2 Completed
49 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
DUET-4
Phase 1 Completed
78 enrolled
PIVOT-02
Phase 1/2 Completed
557 enrolled 22 charts
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1 Completed
15 enrolled
DUET-2
Phase 1 Completed
150 enrolled
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
139 enrolled
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Phase 1/2 Completed
444 enrolled 19 charts
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Phase 1 Completed
Improving Goals of Care Discussion in Advanced Cancer Patients
Phase NA Completed
265 enrolled 9 charts
E-MOSAIC Electronic Tool to Monitor Symptoms
Completed
264 enrolled
EPAC
Phase NA Completed
213 enrolled 20 charts
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Phase 1 Completed
32 enrolled
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Phase 1 Completed
180 enrolled
B-Receptor Signaling in Cardiomyopathy
Completed
99 enrolled
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
Phase 1 Completed
33 enrolled
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Phase 3 Completed
130 enrolled 9 charts
Rapamycin With Grapefruit Juice for Advanced Malignancies
Phase 1 Completed
41 enrolled
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Phase 2 Completed
56 enrolled
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Phase 1 Completed
26 enrolled 13 charts
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Phase 1 Completed
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
Phase 1/2 Completed
20 enrolled